ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase inhibition. How these mutations affect tumor sensitivity to established and novel therapies are active areas of research. Thes...

Descripción completa

Detalles Bibliográficos
Autores principales: Brett, Jamie O., Spring, Laura M., Bardia, Aditya, Wander, Seth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365900/
https://www.ncbi.nlm.nih.gov/pubmed/34392831
http://dx.doi.org/10.1186/s13058-021-01462-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365900/
https://www.ncbi.nlm.nih.gov/pubmed/34392831
http://dx.doi.org/10.1186/s13058-021-01462-3

Ejemplares similares